Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Positive New Data and Strong Recruitment in Pancreatic Cancer Trial
Amplia Enters into Preclinical Collaboration with Korean Specialist Drug Screening Company Next&Bio
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
Categories
Archive
Company News
Investor Newsletters
Videos
22 Aug 2024
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Read More
21 Aug 2024
Fifth partial response confirmed in ACCENT trial
Read More
12 Aug 2024
Amplia receives R&D Tax Rebate
Read More
07 Aug 2024
Key chemical form patents in Europe and Japan
Read More
06 Aug 2024
Fourth partial response confirmed in ACCENT trial
Read More
02 Aug 2024
ASX Briefs podcast | Interview with Dr Chris Burns
Read More
1
